Thank you for taking our Predictive Intelligence survey where we, as a group, can better anticipate and plan for major market events. Survey participants gain exclusive access to the survey results.
Today's question pertains to the outcome of Staar Surgical's upcoming FDA Ophthalmic Devices Advisory Committee Meeting on February 14, 2014. The meeting is slated to discuss a PMA supplement for the device maker's Toric ICL, part of its Visian line of intra-ocular implants.
Staar's implantable Collamer lenses are surgically placed between the iris and the natural lens of the eye in order to correct vision, with the new Toric ICL designed to also help patients with near-sightedness, far-sightedness and astigmatism. The Toric device is already available in markets overseas, where the company estimates that it comprises about half of its sales compared with Staar's standard myopic lenses.
Note: for the purpose of this survey, a 9-0 decision with one abstention would be considered a majority decision, but not unanimous.